1-20 of 41
Eva Medvedova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High-dose anakinra to treat refractory immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy recipients

Free
Emily Liang, Smith Kungwankiattichai, Xiancheng Wu, Jenna Voutsinas, Dwight Macero, Yein Jeon, Yang Qiao, Jennifer Huang, Andrew Portuguese, Francesco Mazziotta, Noam Kopmar, Eshana Shah, Kate Markey, Erik Kimble, Alexandre Hirayama, Aude Chapuis, Ryan Cassaday, Brian Till, Edus Warren, Filippo Milano, Mazyar Shadman, Andy Chen, Amrita Desai, Brandon Hayes-Lattin, Gabrielle Meyers, Sanjog Bastola, Manoj Rai, Jessica Leonard, Jacqueline Trussell, Cheryl Stomberg, Stephen Spurgeon, Craig Okada, Tanaya Shree, Rebecca Silbermann, Eva Medvedova, Bashi Ratterree, Rachel Bixler, Staci Williamson, Qian Wu, Jordan Gauthier, Richard Maziarz
Journal: Blood
Blood (2025) 146 (Supplement 1): 928.
https://doi.org/10.1182/blood-2025-928
Published: 2025
Journal Articles

Redefining function high-risk (FHR) multiple myeloma (MM) in the context of upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Free
Luciano Costa, Susan Bal, Kelly Godby, Gayathri Ravi, Eva Medvedova, Natalie Callander, Rebecca Silbermann, Bhagirathbhai Dholaria, Forest Huls, Baylie Mullinax, Laura Joiner, Caitlin Hagedorn, Binod Dhakal
Journal: Blood
Blood (2025) 146 (Supplement 1): 1037.
https://doi.org/10.1182/blood-2025-1037
Published: 2025
Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Free
Lauren Merz, Rebecca Zon, Susanna Jacobus, Mehmet Samur, Jeffrey Zonder, Abdullah Khan, Hani Hassoun, Larry Anderson, Yvonne Efebera, Tondre Buck, Racquel Innis-Shelton, Monique Hartley-Brown, Sagar Lonial, Erica Campagnaro, Peter Voorhees, Robert Orlowski, Caitlin Costello, Noopur Raje, Eva Medvedova, Philip McCarthy, Carter Milner, Cristina Gasparetto, Mounzer Agha, Krisstina Gowin, Rammurti Kamble, Sundar Jagannath, Nitya Nathwani, Melissa Alsina, Sergio Giralt, Jacob Laubach, Omar Nadeem, Irene Ghobrial, Clifton Mo, Kenneth Anderson, Nikhil Munshi, Paul Richardson
Journal: Blood
Blood (2025) 146 (Supplement 1): 1033.
https://doi.org/10.1182/blood-2025-1033
Published: 2025
Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Free
Peter Voorhees, Meletios Dimopoulos, Yaël Cohen, Fredrik Schjesvold, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Hila Magen, Albert Oriol, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Špička, Anne Mylin, Simon Hallam, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Abdullah Khan, Eva Medvedova, J Christine Ye, Andrew Cowan, Philippe Moreau, María-Victoria Mateos, Hartmut Goldschmidt, Diego Vieyra, Ashta Raval, Linlin Sha, Liang Li, Els Rousseau, Robyn Dennis, Robin Carson, S. Vincent Rajkumar
Journal: Blood
Blood (2025) 146 (Supplement 1): 372.
https://doi.org/10.1182/blood-2025-372
Published: 2025
Journal Articles

Distinct trajectory and prognosis of measurable residual disease (MRD) in t(11;14) multiple myeloma (MM) treated with upfront quadruplet (QUAD) therapy and autologous stem cell transplantation (ASCT)

Free
Luciano Costa, Kelly Godby, Gayathri Ravi, Forest Huls, Eva Medvedova, Binod Dhakal, Bhagirathbhai Dholaria, Natalie Callander, Rebecca Silbermann, Laura Joiner, Caitlin Hagedorn, Baylie Mullinax, Susan Bal
Journal: Blood
Blood (2025) 146 (Supplement 1): 363.
https://doi.org/10.1182/blood-2025-363
Published: 2025
Journal Articles

Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up

Free
Saad Usmani, Shaji Kumar, María-Victoria Mateos, J Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael Chu, Suzanne Trudel, Joshua Richter, Paula Rodriguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey Matous, Laura Rosiñol Dachs, Koichi Onodera, Carmela Maffucci, Emma Scott, Christoph Heuck, Jing Zhang, Todd Henninger, Lisa O'Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Yaël Cohen
Journal: Blood
Blood (2025) 146 (Supplement 1): 698.
https://doi.org/10.1182/blood-2025-698
Published: 2025
Journal Articles

Characterization of a population with newly diagnosed standard risk multiple myeloma by the 2025 ims/IMWG definition with exceptional long-term outcomes after fixed duration therapy

Free
Eva Medvedova, Bhagirathbhai Dholaria, Gayathri Ravi, Binod Dhakal, Rebecca Silbermann, Susan Bal, Kelly Godby, Laura Joiner, Natalie Callander, Luciano Costa
Journal: Blood
Blood (2025) 146 (Supplement 1): 4007.
https://doi.org/10.1182/blood-2025-4007
Published: 2025
Journal Articles

Outcomes of patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant stratified by the 2025 ims/IMWG risk classification

Free
Priyanka Venkatesh, Gayathri Ravi, Kelly Godby, Binod Dhakal, Eva Medvedova, Rebecca Silbermann, Bhagirathbhai Dholaria, Forest Huls, Laura Joiner, Caitlin Hagedorn, Natalie Callander, Luciano Costa, Susan Bal
Journal: Blood
Blood (2025) 146 (Supplement 1): 5799.
https://doi.org/10.1182/blood-2025-5799
Published: 2025
Journal Articles

Optimal MRD-based end point to support response-adapted treatment cessation in newly diagnosed multiple myeloma

Available to Purchase
Clinical Trials & Observations
Smith Giri, Binod Dhakal, Natalie S. Callander, Eva Medvedova, Kelly Godby, Bhagirathbhai R. Dholaria, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca W. Silbermann, Luciano Costa
Journal: Blood
Blood (2025) 146 (6): 707–716.
https://doi.org/10.1182/blood.2024027674
Published: 2025
Includes: Supplemental data
Journal Articles

Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial

Free
Natalie Callander, Gayathri Ravi, Rebecca W. Silbermann, Zhubin J. Gahvari, Eva Medvedova, Bhagirathbhai Dholaria, Naresh Bumma, Doris K. Hansen, Everette M Colquette, Pamela Hardwick, Luciano J. Costa
Journal: Blood
Blood (2024) 144 (Supplement 1): 3365.
https://doi.org/10.1182/blood-2024-210652
Published: 2024
Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Free
Binod Dhakal, Rebecca Silbermann, Timothy M Schmidt, Eva Medvedova, Susan Bal, Smith Giri, Naresh Bumma, Abdullah Mohammad Khan, Andrew J. Cowan, Rajshekhar Chakraborty, Gayathri Ravi, Kelly Godby, Bhagirathbhai Dholaria, Muhamed Baljevic, Bria Gendron, Aimaz Afrough, Gurbakhash Kaur, Mary Kwok, Rahul Banerjee, Zhubin Ghavari, Anita D'Souza, Othman S. Akhtar, Meera Mohan, Henning Schade, Ravi Narra, Yubin Kang, Jeffrey V Matous, Larry D Anderson, Jr., Natalie Callander, Luciano J. Costa
Journal: Blood
Blood (2024) 144 (Supplement 1): 2000.1.
https://doi.org/10.1182/blood-2024-200210
Published: 2024
Journal Articles

Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM)

Free
Smith Giri, Binod Dhakal, Natalie Callander, Eva Medvedova, Kelly Godby, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca W. Silbermann, Luciano J. Costa
Journal: Blood
Blood (2024) 144 (Supplement 1): 257.
https://doi.org/10.1182/blood-2024-205611
Published: 2024
Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Free
Meletios-Athanasios Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold, Yael C. Cohen, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross Ian Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Albert Oriol, Gabor Mikala, Gonzalo Martin Garate, Koen Theunissen, Ivan Spicka, Anne K. Mylin, Sara Bringhen, Katarina Uttervall, Bartosz Michal Pula, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, Vincent Rajkumar
Journal: Blood
Blood (2024) 144 (Supplement 1): 773.
https://doi.org/10.1182/blood-2024-201057
Published: 2024
Journal Articles

Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation

Free
Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai Dholaria, Smith Giri, Saurabh Chhabra, Susan Bal, Kelly Godby, Gayathri Ravi, Rebecca W. Silbermann, Natalie Callander
Journal: Blood
Blood (2024) 144 (Supplement 1): 363.
https://doi.org/10.1182/blood-2024-201914
Published: 2024
Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Free
Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah
Journal: Blood
Blood (2023) 142 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2023-182345
Published: 2023
Journal Articles

A Phase 2 Study of Nivolumab for Relapsed/Refractory Multiple Myeloma or Non-Hodgkin Lymphoma Following CAR-T Therapy

Free
Rahul Banerjee, Ryan C Lynch, Qian Wu, Sylvain Simon, Chaitra S Ujjani, Brian G Till, Natalie Wuliji, Daria Gausman, Joshua Dizon, Mary L. Kwok, Sarah S. Lee, Rebecca Silbermann, Eva Medvedova, David G Maloney, Jorge Daniel Ramos, Mazyar Shadman, Jordan Gauthier, Cameron J. Turtle, Ajay K Gopal, Damian J Green, Stanley R. Riddell, Andrew J. Cowan
Journal: Blood
Blood (2023) 142 (Supplement 1): 3509.
https://doi.org/10.1182/blood-2023-173202
Published: 2023
Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Free
Christiane A. Houde, Abdullah Khan, Susanna J. Jacobus, Hani Hassoun, Larry D. Anderson, Jr., Lauren E. Merz, Rebecca L. Zon, Yvonne Efebera, Tondre Buck, Racquel D. Innis-Shelton, Monique A Hartley-Brown, Sagar Lonial, Erica L. Campagnaro, Peter M. Voorhees, Robert Z. Orlowski, Edward Libby, David Duane Hurd, Caitlin L. Costello, Noopur S. Raje, Eva Medvedova, Philip L. McCarthy, Carter P. Milner, Cristina Gasparetto, Mounzer E Agha, Krisstina Gowin, Rammurti T. Kamble, Sundar Jagannath, Nitya Nathwani, Melissa Alsina, Sergio A. Giralt, Jacob P. Laubach, Omar Nadeem, Irene M. Ghobrial, Clifton C. Mo, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Paul G. Richardson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4762.
https://doi.org/10.1182/blood-2023-181032
Published: 2023
Journal Articles

Patterns of Change in Multiple Myeloma (MM) Clone Size with Autologous Hematopoietic Stem Cell Transplantation (ASCT) Assessed By Next Generation Sequencing (NGS) in Patients (pts) Receiving Modern Therapy

Free
Tylan Magnusson, Luciano Costa, Smith Giri, Gayathri Ravi, Kelly Godby, Binod Dhakal, Bhagirathbhai Dholaria, Eva Medvedova, Natalie S. Callander, JoAnn Steele, Kathy Langley, Baylie Mullinax, Melissa Sentell, Stephen Horn, Candace Hill, Megan Boullion, Susan Bal
Journal: Blood
Blood (2023) 142 (Supplement 1): 2214.
https://doi.org/10.1182/blood-2023-187343
Published: 2023
Journal Articles

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies

Free
Natalie Callander, Rebecca Silbermann, Jonathan L. Kaufman, Kelly N. Godby, Jacob P Laubach, Timothy Martin Schmidt, Douglas W Sborov, Eva Medvedova, Brandi Reeves, Binod Dhakal, Cesar Rodriguez, Saurabh Chhabra, Ajai Chari, Susan Bal, Larry D. Anderson, Jr., Bhagirathbhai Dholaria, Nitya Nathwani, Parameswaran Hari, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Ken H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S. Lin, Smith Giri, Luciano J. Costa, Paul G. Richardson, Saad Usmani, Peter M. Voorhees
Journal: Blood
Blood (2022) 140 (Supplement 1): 10144–10147.
https://doi.org/10.1182/blood-2022-160451
Published: 2022
Journal Articles

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the Master Trial

Free
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Timothy Martin Schmidt, Bhagirathbhai Dholaria, Kelly N. Godby, Rebecca Silbermann, Susan Bal, Anita D'Souza, Smith Giri, James L. Omel, Parameswaran Hari, Natalie Callander, Binod Dhakal
Journal: Blood
Blood (2022) 140 (Supplement 1): 7275–7277.
https://doi.org/10.1182/blood-2022-156730
Published: 2022